The efficiency and safty level of nab-PTX 80% dose therapy for advanced gastric cancer as a second line chemotherapy

The efficiency and safty level of nab-PTX 80% dose therapy for advanced gastric cancer as a second line chemotherapy - NPEG-C

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016988

Enrollment

Registered

2015-06-01

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

To give 80% dose down nab-PTX (260mg / m2 tri-weekly) for gastric cancer patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PD patients after recieving standard first therapy for gastric cancer

Exclusion criteria

Exclusion criteria: patients who have serious complications

Design outcomes

Primary

Measure	Time frame
PSF,RR,OS	—

Countries

Japan

Contacts

Public ContactTomoyuki Shibata

Fujita Health University Gastroenterology

tshibata-04@umin.ac.jp+81-562-93-9240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026